Естония -
естонски -
Ravimiamet
tagrisso tablett
astrazeneca ab - osimertiniib - tablett - 80mg 25tk
Естония -
естонски -
Ravimiamet
entocort rektaalsuspensiooni tablett ja lahusti
astrazeneca uk limited - budesoniid - rektaalsuspensiooni tablett ja lahusti - 2mg 7tk
Естония -
естонски -
Ravimiamet
marcain-adrenalin süstelahus
astrazeneca ab - bupivakaiin+epinefriin (adrenaliin) - süstelahus - 5mg+5mcg 1ml 20ml 5tk
Естония -
естонски -
Ravimiamet
symbicort turbuhaler inhalatsioonipulber
astrazeneca ab - formoterool+budesoniid - inhalatsioonipulber - 4,5mcg+80mcg 1annus 120annus 1tk
Естония -
естонски -
Ravimiamet
imfinzi infusioonilahuse kontsentraat
astrazeneca ab - durvalumab - infusioonilahuse kontsentraat - 50mg 1ml 10ml 1tk
Естония -
естонски -
Ravimiamet
marcaine adrenaline 5mg/ml+5mcg/ml süstelahus
astrazeneca ab - bupivakaiin+epinefriin (adrenaliin) - süstelahus - 5mg+5mcg 1ml 20ml 5tk
Европейски съюз -
естонски -
EMA (European Medicines Agency)
beyfortus
astrazeneca ab - nirsevimab - suguhormoonid ja immunoglobuliinid, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.
Естония -
естонски -
Ravimiamet
lokelma suukaudse suspensiooni pulber
astrazeneca ab - naatriumtsirkooniumtsüklosilikaat - suukaudse suspensiooni pulber - 10mg 30tk
Естония -
естонски -
Ravimiamet
pulmicort turbohaler inhalatsioonipulber
astrazeneca ab - budesoniid - inhalatsioonipulber - 200mcg 1annus 200annus 1tk
Европейски съюз -
естонски -
EMA (European Medicines Agency)
nubeqa
bayer ag - darolutamide - prostatic kasvajad, kastreerimine-vastupidavad - endokriinset ravi - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.